Phase 4 N=162 Single-blind

Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora

Bacterial Conjunctivitis

Bottom Line

View on ClinicalTrials.gov: NCT00312338 ↗

Enrolled (actual)

162

Serious AEs

0.0%

Results posted

Feb 2010

Primary outcome: Primary: Susceptability Changes in Streptococcus Pneumoniae Distal to the Site of Instillation — 0; 0; 0; 0 Percent of resistant isolates

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: VIGAMOX (Drug)
Age: Pediatric · 1+ yrs
Sex: All
Sponsor: Alcon Research
Primary completion: Jun 2007

Outcome Measures

Outcome	Result	p-value
PRIMARY Susceptability Changes in Streptococcus Pneumoniae Distal to the Site of Instillation	0; 0; 0; 0	—
PRIMARY Susceptability Changes in Staphylococcus Aureus Distal to the Site of Instillation	8.3; 0; 0; 0	—
PRIMARY Susceptability Changes in Haemophilus Influenzae Distal to the Site of Instillation	0; 0; 0; 0	—

Summary

Topical Treatment of Bacterial Conjunctivitis and its Effect on Microbial Flora

Eligibility Criteria

Inclusion Criteria

Patients from 1 to 13 years of age that have diagnosis of bacterial conjunctivitis in either or both eyes (for 2 days

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00312338). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.